Evidence map›Paper›PMID 20107430›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2010

A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia.

Arun K Tiwari, Clement C Zai, Olga Likhodi, Annika Lisker, Deepika Singh, Renan P Souza, Poonam Batra, Syed H E Zaidi, Sheng Chen, Fang Liu and 5 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01844700 (1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01844700 phase4terminatednot on this mapstarted 2013, after this paper: background citation

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

TypeinterventionalSponsorNorthwell HealthRan2013 to 2014Enrolled14ConditionsHigh Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime ExposureArmsZiprasidone, aripiprazole, quetiapine, or risperidone
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.Behavioral sciences (Basel, Switzerland) · 2021
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Arun K TiwariDepartment of Neuroscience, Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Clement C Zai
Olga Likhodi
Annika Lisker
Deepika Singh
Renan P Souza
Poonam Batra
Syed H E Zaidi
Sheng Chen
Fang Liu
Imke Puls
Herbert Y Meltzer
Jeffrey A Lieberman
James L Kennedy
Daniel J Müller
Centre for Addiction and Mental Health · CACharité - Universitätsmedizin Berlin · DEUniversity of Toronto · CAColumbia University · USVanderbilt Psychiatric Hospital · US

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Antipsychotic-induced weight gain has emerged as a serious complication in the treatment of patients with atypical antipsychotic drugs. The cannabinoid receptor 1 (CNR1) is expressed centrally in the hypothalamic region and associated with appetite and satiety, as well as peripherally. An antagonist of CNR1 (rimonabant) has been effective in causing weight loss in obese patients indicating that CNR1 might be important in antipsychotic-induced weight gain. Twenty tag SNPs were analyzed in 183 patients who underwent treatment (with either clozapine, olanzapine, haloperidol, or risperidone) for chronic schizophrenia were evaluated for antipsychotic-induced weight gain for up to 14 weeks. The polymorphism rs806378 was nominally associated with weight gain in patients of European ancestry treated with clozapine or olanzapine. 'T' allele carriers (CT+TT) gained more weight (5.96%), than the CC carriers (2.76%, p=0.008, FDR q-value=0.12). This translated into approximately 2.2 kg more weight gain in patients carrying the T allele than the patients homozygous for the CC genotype (CC vs CT+TT, 2.21+/-4.51 vs 4.33+/-3.89 kg; p=0.022). This was reflected in the allelic analysis (C vs T allele, 3.84 vs 5.83%, p=0.035). We conducted electrophoretic mobility shift assays which showed that the presence of the T allele created a binding site for arylhydrocarbon receptor translocator (ARNT), a member of the basic helix-loop-helix/Per-Arnt-Sim protein family. In this study, we provide evidence that the CNR1 gene may be associated with antipsychotic-induced weight gain in chronic schizophrenia patients. However, these observations were made in a relatively small patient population; therefore these results need to be replicated in larger sample sets.

Indexed as

AdolescentAdultAntipsychotic AgentsAryl Hydrocarbon Receptor Nuclear TranslocatorDNA Mutational AnalysisFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic TestingGenotypeHumansMaleMiddle AgedObesityPolymorphism, GeneticProtein BindingAntipsychotic AgentsARNT protein, humanAryl Hydrocarbon Receptor Nuclear TranslocatorReceptor, Cannabinoid, CB1

Identifiers

PMID20107430
PMCPMC3055343
OpenAlexW2094416210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.